Downregulation of androgen receptors by NaAsO2 via inhibition of AKT‐NF‐κB and HSP90 in castration resistant prostate cancer
- 30 May 2017
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 77 (10) , 1128-1136
Abstract
Background: Androgen and androgen receptor (AR) play essential roles in the development and maintenance of prostate cancer. The recently identified AR splice variants (AR‐Vs) have been considered as a plausible mechanism for the primary resistance against androgen deprivation therapy (ADT) in castration‐resistant prostate cancer (CRPC). Sodium meta‐arsenite (NaAsO2; KML001; Kominox), a trivalent arsenical, is an orally bioavailable and water soluble, which is currently in phase I/II clinical trials for the treatment of prostate cancer. It has a potent anti‐cancer effect on prostate cancer cells and xenografts. The aim of this study was to examine the effect of NaAsO2 on AR signaling in LNCaP and 22Rv1 CRPC cells.Methods: We used hormone‐sensitive LNCaP cells, hormone‐insensitive 22Rv1 cells, and CRPC patient‐derived primary cells. We analyzed anti‐cancer effect of NaAsO2 using real‐time quantitative reverse transcription‐PCR, Western blotting, immunofluorescence staining and CellTiter Glo® luminescent assay. Statistical evaluation of the results was performed by one‐way ANOVA.Results: NaAsO2 significantly reduced the translocation of AR and AR‐Vs to the nucleus as well as their level in LNCaP and 22Rv1 cells. Besides, the level of the prostate‐specific antigen (PSA), downstream target gene of AR, was also decreased. This compound was also an effective modulator of AKT‐dependent NF‐κB activation which regulates AR. NaAsO2 significantly inhibited phosphorylation of AKT and expression and nuclear translocation of NF‐κB. We then investigated the effect of NaAsO2 on AR stabilization. NaAsO2 promoted HSP90 acetylation by down‐regulating HDAC6, which reduces the stability of AR in prostate cancer cells.Conclusions: Here, we show that NaAsO2 disrupts AR signaling at multiple levels by affecting AR expression, stability, and degradation in primary tumor cell cultures from prostate cancer patients as well as CRPC cell lines. These results suggest that NaAsO2 could be a novel therapeutics for prostate cancer.Keywords
Funding Information
- Asan Institute for Life Sciences, Asan Medical Center (W16‐686)
This publication has 41 references indexed in Scilit:
- Cancer Incidence Trends Among Asian American Populations in the United States, 1990-2008JNCI: Journal of the National Cancer Institute, 2013
- New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling PathwayClinical Cancer Research, 2011
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantJournal of Clinical Investigation, 2010
- NF-κB Regulates Androgen Receptor Expression and Prostate Cancer GrowthThe American Journal of Pathology, 2009
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant GrowthCancer Research, 2009
- Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: Roles of ERK/MAP kinaseThe Prostate, 2009
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate CancerCancer Research, 2008
- The Nuclear Factor-κB Pathway Controls the Progression of Prostate Cancer to Androgen-Independent GrowthCancer Research, 2008
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Hsp90 Regulates Androgen Receptor Hormone Binding Affinity in VivoJournal of Biological Chemistry, 1996